Leukocytapheresis with double column, Cellsorba E for refractory ulcerative colitis

Leukocytapheresis with double column, Cellsorba E for refractory ulcerative colitis - LEADER study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023734

Enrollment

Registered

2016-08-24

Start date

2016-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

four-times leukocytoapheresis with double column

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.refractory ulcerative colitis 2.written informed consent

Exclusion criteria

Exclusion criteria: 1.proctitis type 2.under the age of 20 3.patients taking ACE inhibiter 4.patients with hypersensitivity to nafamostat mesylate

Design outcomes

Primary

Measure	Time frame
endoscopic findings at two-weeks after the first LCAP	—

Secondary

Measure	Time frame
1. clinical efficacy at 2, 4 and 24 weeks after the first LCAP 2. fecal occult blood at 2, 4 and 24 weeks after the first LCAP 3. histological findings at 2 and 24 weeks after the first LCAP 4. endoscopic findings at 24weeks later	—

Countries

Japan

Contacts

Public ContactHidezumi Kikuchi

Hirosaki University Graduate School of Medicine Dept. Gastroenterology and Hematorogy

hidezumi@hirosaki-u.ac.jp0172-33-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026